ReviewAntibiotics (Basel, Switzerland)2021
Treatment of UTIs Due to
Review in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- "One Health" perspective on prevalence of co-existing extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae: a comprehensive systematic review and meta-analysis.Annals of clinical microbiology and antimicrobials · 2023Pooled it
- Development andMicrobiology spectrum · 2026Article
- Immunomodulatory Role of Milk on Gut Microbiota: Implications for Enhancing Oral Vaccine Efficacy.Probiotics and antimicrobial proteins · 2026Review
- Carbapenem resistance and hypervirulence iniScience · 2026Review
- Phenotypic and genotypic characterization of carbapenem resistant Klebsiella pneumoniae clinical isolates from Damietta, Egypt.BMC microbiology · 2026Article
- Bacterial distribution and drug resistance patterns of urinary tract infection in tuberculosis patients: a 5-year retrospective study.Frontiers in microbiology · 2026Article
- An integrated wearable fluorescence sensor for E. coli detection in catheter bags.Biosensors & bioelectronics · 2025Article
- Urinary Multidrug-ResistantMicroorganisms · 2025Article
- Mapping Antimicrobial Resistance inDiagnostics (Basel, Switzerland) · 2025Article
- Prediction of higher ceftazidime-avibactam concentrations in the human renal interstitium compared with unbound plasma using a minimal physiologically based pharmacokinetic model developed in rats and pigs through microdialysis.Antimicrobial agents and chemotherapy · 2025Article
- Nanomaterials for the Treatment of Contamination by Nosocomial Pathogens in Intensive Care Units.International journal of nanomedicine · 2025Review
- Phage Therapy: A Promising Treatment Strategy against Infections Caused by Multidrug-resistantCurrent pharmaceutical design · 2025Review
- A Possible Tool for Guiding Therapeutic Approaches to Urinary Infections withAntibiotics (Basel, Switzerland) · 2024Article
- Influence of preoperative urine culture and bacterial species on urogenital sepsis after ureteral flexible lithotripsy in patients with upper urinary tract stones.Frontiers in medicine · 2024Article
- Hybrid Sequencing-Based Genomic Analysis ofInfection and drug resistance · 2024Article
- Clonal Spread of Carbapenem-Resistant Klebsiella pneumoniae Sequence Type 11 in Chinese Pediatric Patients.Microbiology spectrum · 2022Article
- Silver Nanoparticles and Its Mechanistic Insight for Chronic Wound Healing: Review on Recent Progress.Molecules (Basel, Switzerland) · 2022Review
- A Potent Antibiotic Combination of Linezolid and Polymycin B Nonapeptide AgainstFrontiers in pharmacology · 2022Article
- Analysis of the Distribution and Drug Resistance of Pathogens in Patients with Urinary Tract Infection in the Eastern Chongming Area of Shanghai from 2018 to 2020.Infection and drug resistance · 2022Article
- Urinary Tract Infections Caused byFrontiers in cellular and infection microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background
methodsthis narrative review of the literature was performed according to the criteria of preferred reporting items for systematic review and meta-analyses statement (PRISMA) (2020). RESULTS AND
conclusionsKPCp-UTIs are a real challenge for physicians. While cefiderocol, meropenem-vaborbactam, ceftazidim-avibactam, and imipenem-relebactam represent a major step forward in the treatment of these UTIs, no guidelines are currently available, in view of choosing the most appropriate treatment, in each specific case.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.